Investing

Investment analysis, share recommendations, and market insights.

Premium

Two speculative miners

Here are two situations where the odds might be on the side of the speculators! But always remember the risk.

James Dunn · August 5, 2024
Premium

HOT stock: Pro Medicus (PME)

In our “HOT” stock column, Michael Gable, managing director of Fairmont Equities, explains why he’s still a buyer of PME for his clients.

Maureen Jordan · August 1, 2024
Premium

Is Macquarie a buy over $200?

I’m a great believer in backing track record, so there’s no argument from me when it comes to Macquarie. It is, and remains, a core portfolio stock. The question however is where it sits in the current market: is this a point to acquire more, ease back a touch and take a profit on a small portion, or just sit back?

Paul Rickard · July 29, 2024
Premium

4 cancer fighting stocks

The ASX has a burgeoning life sciences cohort doing great work in a range of major diseases. Here are four interesting cancer fighters.

James Dunn · July 29, 2024
Premium

“HOT” stock: Audinate (ASX:AD8)

In our “HOT” stock column, Michael Wayne, Managing Director of Medallion Financial Group, says that for investors who feared they may have missed their chance with Audinate, the current price may present an attractive opportunity to begin accumulating a high-quality growth business during a pull-back.

Maureen Jordan · July 25, 2024

You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.